Clinical Trial Update: Vascular Effects of Mineralocorticoid Receptor Antagonism in Kidney Disease [Phase 2]

View source ↗

Summary

Phase 2 trial assessing vascular effects of mineralocorticoid receptor antagonism in chronic kidney disease with albuminuria.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Albuminuria
• Chronic Kidney Disease

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Chronic Kidney Disease, Albuminuria | Phase 2 | Status: COMPLETED | Results posted: 2022-12-21